Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509016 | 0.87 | PTGDR2 (0.40) | LMNAHTTNR1D1PDE4APDE4B | |
| SCHEMBL508180 | 0.84 | NPC1 (0.43) | LMNAPTGDR2KMT2AALDH1A1 | |
| SCHEMBL10996751 | 0.77 | MAPT (0.53) | LMNAHTTNR1D1KMT2AMEN1 | |
| SCHEMBL508775 | 0.74 | PTGDR2 (0.48) | LMNAHTTNR1D1PDE4APDE4B | |
| SCHEMBL508765 | 0.74 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL28881348 | 0.70 | RAB9A (0.45) | LMNAHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL12195291 | 0.70 | KDM4E (0.56) | LMNAHTTALDH1A1MAPT | |
| SCHEMBL16656263 | 0.70 | KDM4E (0.56) | LMNAHTTALDH1A1MAPT | |
| SCHEMBL12466468 | 0.69 | LMNA (0.48) | LMNAPTGDR2KMT2AMEN1 | |
| SCHEMBL30796999 | 0.69 | TSHR (0.51) | LMNANR1D1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528901-B9 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-2528901-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8791272-B2 | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2528901-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092140-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH3 | LMNA 3633/4885HTT 4212/4885NR1D1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.